Malignant Thoracic Neoplasm

In an advanced lung adenocarcinoma patient harboring EGFR G719S mutation, EGFR G719S was reported to be sensitive to erlotinib treatment. The patient was initially treated with standard chemotherapy, … (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

In an in vitro study, a NIH-3T3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment compared to NIH-3T3 cells expressing EGFR wild-type. Sensitivity was determine… (full text at CIViC)

PMID 16187797 · Greulich et al., 2005 · Open in CIViC

Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.

PMID 15118125 · Paez et al., 2004 · Open in CIViC

In vitro studies showed that cells with S768I mutation had moderate sensitivity (IC50=90-315nM) to gefitinib , in comparison to the del747-753insS (IC50= 7nM) or L858R (IC50=12-20nM) mutations that co… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

This small clinical (n=56) study suggests that patients with minor mutations of EGFR, like G719S, are likely to have a moderate response to Tyrosine kinase inhibitors like Gefitinib and Erlotinib. In … (full text at CIViC)

PMID 26124334 · Otsuka et al., 2015 · Open in CIViC

Study found somatic EGFR mutations localized to exons 19,21 in 8/9 patients who exhibited a response to Gefitinib treatment. Of these mutations 7/8 were localized near the ATP cleft Gefitinib targets,… (full text at CIViC)

PMID 15118073 · Lynch et al., 2004 · Open in CIViC

A 58-year-old male with stage IVB lung adenocarcinoma presented with respiratory symptoms and widespread metastases. NGS revealed EGFR-GNAT3 fusion (EGFR exons 1–24 to GNAT3 exon 8; 76.3% abundance) a… (full text at CIViC)

PMID 38595815 · Wang et al., 2024 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

A 74 year old female former smoker with 8 pack years and EGFR H773_V774insH lung adenocarcinoma patient was given erlotinib as second line treatment, and had progressive disease as best response with … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

The del I744_K745insKIPVAI mutation was found in a 36-year-old former female smoker, with an adenocarcinoma of the lung. She received erlotinib at a 150 mg daily dose. A clinical meaningful improvemen… (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was tre… (full text at CIViC)

PMID 27569104 · Kocoglu et al., 2016 · Open in CIViC

194 somatic mutations seen in primary lung cancers were functionally evaluated using three approaches: (1) differences in pattern or extent of changes in gene expression in A549 cells induced by trans… (full text at CIViC)

PMID 27478040 · Berger et al., 2016 · Open in CIViC

In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (4… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib. The pati… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with erlotinib suppressed phosphorylation of EGFR L858R+C797S but did not decrease phosphory… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC)

PMID 22452896 · Miller et al., 2012 · Open in CIViC

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

In a study, 2 participants with stage IV adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have L747P mutation and were treated with the 1st generation TKIs gefitinib … (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC)

PMID 22452896 · Miller et al., 2012 · Open in CIViC

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC)

PMID 22452896 · Miller et al., 2012 · Open in CIViC

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC)

PMID 19671843 · Jackman et al., 2009 · Open in CIViC